Telescope Innovations Participates in Canadian Delegation to BIX 2026

Vancouver, British Columbia-based Telescope Innovations Corp., a leading developer of Physical AI systems, including Self-Driving Laboratories, is set to participate in the Canadian delegation to the BIOPLUS-INTERPHEX Korea (BIX) 2026, taking place from October 27 to 30, 2026, in Seoul, South Korea. The company will be represented by its Founder and Chief Technology Officer, Professor Jason Hein, and Vice President of Operations, Paloma Prieto.

Telescope Innovations has an established presence in Korea, having deployed the country's first Self-Driving Lab for biopharmaceutical research, development, and education. This system was installed at the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) in Seoul in December 2025. Canada has been designated as the Country of Honour for BIX 2026, positioning Canadian life sciences innovators at the center of one of Asia's leading biopharma and biomanufacturing events.

During the mission, Telescope will participate in industry visits organized by the Trade Commissioner Service and the Health Emergency Readiness Canada (HERC). The company will deliver presentations on the application of Physical AI and Self-Driving Laboratories to pharmaceutical R&D and engage in one-on-one business matchmaking meetings with prospective partners, customers, and investors.

The company's participation in BIX 2026 is part of its ongoing efforts to strengthen its international presence and relationships within the life sciences sector.

Telescope Innovations Corp. is a leading developer of Physical AI systems, including Self-Driving Laboratories, and enabling technologies and services for the global pharmaceutical and high-value chemical industries. The company's Self-Driving Laboratories are autonomous platforms that combine robotics, real-time analytics, and artificial intelligence to plan, execute, and analyze chemistry experiments with greater speed, consistency, and data quality than manual approaches.

The company also develops and sells enabling technologies, including the DirectInject-LC™ reaction sampling system, and provides contract process development services. Bio-pharmaceutical, specialty chemical, and advanced materials companies use Telescope's products and services to accelerate the development and scale-up of chemical processes, reducing time and cost from laboratory to market.

Telescope Innovations Corp. is committed to expanding its international footprint and collaborating with organizations seeking to accelerate R&D through advanced automation and artificial intelligence technologies. The company's participation in BIX 2026 is expected to provide a significant platform for strengthening its presence within Asia's rapidly expanding biopharmaceutical market.